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Autism is a neurodevelopmental disorders characterized by impairments in communication
and social behavior, and by repetitive behaviors. Although genetic factors might be largely
responsible for the occurrence of autism they cannot fully account for all cases and it is
likely that in addition to a certain combination of autism-related genes, specific environ-
mental factors might act as risk factors triggering the development of autism. Thus, the
role of environmental factors in autism is an important area of research and recent data
will be discussed in this review. Interestingly, the results show that many environmental
risk factors are interrelated and their identification and comparison might unveil a common
scheme of alterations on a contextual as well as molecular level. For example, both, dis-
ruption in the immune system and in zinc homeostasis may affect synaptic transmission
in autism. Thus, here, a model is proposed that interconnects the most important and
scientifically recognized environmental factors. Moreover, similarities in how these risk
factors impact synapse function are discussed and a possible influence on an already well
described genetic pathway leading to the development of autism via zinc homeostasis is
proposed.
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INTRODUCTION
In the last decade, multiple genes have been implicated in autism,
collectively accounting for approximately 15% of cases includ-
ing autism spectrum disorders (ASDs; Abrahams and Geschwind,
2010). In this context, an increasing number of ASDs can be attrib-
uted to rare genetic changes that are either inherited or appear
de novo and further mutations and candidate genes are increas-
ingly identified. Besides a handful of single specific genes that
can be associated with autism, the current theory supports the
idea of a polygenic inheritance, meaning that multiple genes are
likely to be involved that may predispose an individual to develop
autism. Although inherited factors might be largely responsible
for the occurrence of autism, it is equally clear that genetic aber-
rations cannot fully account for all cases of autism. The California
Autism Twins Study (CATS) for example, with 192 identical and
fraternal twin pairs shows a concordance rate of 77% for male
monozygotic twins and 50% for female identical twins. The rates
among fraternal twins were 31% (male) and 36% (female; Hall-
mayer et al., 2011). The concordance rate of 31/36% of fraternal
twins is higher than the observed rate of 3–14% between siblings of
different ages. Thus, in addition to a genetic heritability, common
factors such as the shared prenatal environment might play a role
in the formation of ASD. Moreover, the increasing prevalence of
autism has drawn attention to the potential involvement of toxins
in our environment. Extending the theory of pure genetic causes,
it seems likely that in addition to a certain combination of autism-
related genes, exposure to specific environmental factors might
be necessary to trigger the development of autism in some indi-
viduals. However, environmental risk factors do not solely cover
the exposure to toxins but include all changes other than those
on a DNA – level such as maternal nutrition, infection during
pregnancy, and prematurity as well as parental age at conception.
This review highlights the role of environmental risk factors
in autism in the context of emerging genetic research which sug-
gests that the synapse is an organelle particularly vulnerable to
genetic disruption and possibly disruption by related environ-
mental influences. In particular, recent data suggest that immune
system abnormalities and altered zinc homeostasis may affect
synaptic transmission. Understanding how genetic and environ-
mental risk factors in autism converge at synapses might provide
a valuable starting point for future work towards uncovering the
patho-mechanisms of autism.
Autism is a developmental disorder and most cases are diag-
nosed by the age of three and as early as 14 months (Landa,
2008). Nonetheless, autism might be present from birth on rather
than develop within this developmental time window. Thus, pre-
natal environmental factors are of considerable interest for the
development of autism (Table 1).
PRENATAL VIRAL INFECTION
Failures in early fetal brain development have been linked to a
higher risk for autism and attention has been drawn to offspring
exposed to viral or bacterial infections in utero (Arndt et al.,
2005; Libbey et al., 2005; Miller et al., 2005; Patterson, 2009). For
instance, infections that have been associated with autism include
prenatal influenza, rubella, and cytomegalovirus infections (Pardo
et al., 2005). However, the outcome of exposure to a prenatal viral
infection depends on many factors such as maternal immune sta-
tus, susceptibility of the maternal and fetal host, the developmental
stage of the fetus, the amount of virus reaching the fetus, the
route of access and the infecting virus, and strain of virus (Blat-
tner, 1974). Nevertheless, given the variety of viruses and their
pathogenic effects that can be associated with autism, immuno-
logical imbalance in general might be an underlying risk factor for
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Table 1 | Summary of the presented environmental risk factors for autism.
Risk factor Reference Quality of evidence
produced by the studies
Prenatal viral
infection
Maternal infection, autoimmune disease,
and/or allergy could alter the immune
status of the fetal brain and the fetal
immune system in general
Arndt et al. (2005), Libbey et al.
(2005), Miller et al. (2005), Patterson
(2009), Pardo et al. (2005), Blattner
(1974), Meyer et al. (2007), Fox et al.
(2012), Anderson et al. (2007)
The results have been replicated multiple times
and the evidence for an association of altered
immune status and ASD is strong and growing
Zinc deficiency A high incidence rate of zinc deficiency is
seen in autistic children. Maternal/early
developmental zinc deficiency might
provide a mechanism of
gene/environment interaction
Lakshmi Priya and Geetha (2011),
Faber et al. (2009), Jen and Yan
(2010), Walsh et al. (2001, 2002),
Yasuda et al. (2011), Golub et al.
(1995), Sandstead et al. (1978)
The results have been replicated multiple times,
recently using a large cohort of 1,967 autistic
children. Based on the data, a strong association
of zinc deficiency and autism is found
Abnormal
melatonin
synthesis
Genetic abnormalities and/or
environmental factors may influence
melatonin synthesis. Melatonin regulates
the circadian rhythm, is an antioxidant, is
involved in the immune response, and
regulates synaptic plasticity
Rossignol and Frye (2011), Cortesi
et al. (2010), Melke et al. (2008),
Feng et al. (2012)
Few but high-quality studies report an
association of abnormal melatonin synthesis
and autism. Genetic studies hint towards a
decrease in melatonin as causative rather than
aftereffect of autism. However, more research is
needed to strengthen the association and
propose a patho-mechanism
Maternal
diabetes
Obesity and diabetes occur more
frequently in mothers of ASD cases.
Diabetes in the mother during pregnancy
leads to a twofold increased risk
Gardener et al. (2009), Krakowiak
et al. (2012)
Meta-analysis confirmed maternal diabetes as
risk factor. However, the number of studies is
small and others have not found a significant
association. It is likely that in some cases of
diabetes, downstream effects might act as risk
factor for autism. However, more molecular
biological research is needed to identify the
possible patho-mechanisms
Prenatal and
perinatal
stress
Autism has been reported to be
associated with prenatal stress. In
animals, regardless of the specific
prenatal stressor used, prenatal stress
activated the HPA axis resulting in
abnormalities in postnatal immune
function
Ward (1990), Beversdorf et al.
(2005), Kinney et al. (2008),
Limperopoulos et al. (2007)
Stress can refer to factors that range from
mechanical to purely psychological ones. The
best association of “stress” with autism is seen
by factors activating the HPA axis, which might
be related to alterations in the immune system.
Future research will have to closer investigate
specific stressors and the related cellular and
molecular alteration
Toxins The incidence of autism is significantly
higher in children prenatally exposed to
valproic acid or thalidomide.
Organophosphate and organochlorine
pesticides may contribute to autism as
well as psychiatric drugs taken by the
mother during pregnancy
Moore et al. (2000), Stromland et al.
(1994), Kolozsi et al. (2009), Kumar
and Chhibber (2011), Kumar et al.
(2010), Karr et al. (2007), Dufault
et al. (2012), Roberts et al. (2007),
Szpir (2006), Gardener et al. (2009)
A limited number of cases and studies makes
the findings hard to interpret resulting in a
rather weak association of toxins as risk factor
and the development of autism. A more solid
association can be found in the use of
psychiatric drugs in the mother during
pregnancy. However, this association might be
explained in a number of ways, which need
further investigation
Parental age The risk to develop autism is associated
with advanced age in either parent. While
most mutations accumulate in the
paternal germline, advanced maternal age
might contribute through mechanisms
such as increased pregnancy
complications and maternal autoimmunity
Gardener et al. (2009), Shelton et al.
(2010), Parner et al. (2012), Sandin
et al. (2012), Kong et al. (2012), van
Balkom et al. (2012),
Buizer-Voskamp et al. (2011),
Grether et al. (2009), Croen et al.
(2007), Reichenberg et al. (2010)
Meta-analysis of multiple studies confirmed
parental age as risk factor for ASD. The result is
underlined by recent genetic studies specifically
revealing an increased paternal mutation rate as
possible patho-mechanism
(Continued)
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Table 1 | Continued
Risk factor Reference Quality of evidence
produced by the studies
Postnatal risk factors Gastrointestinal or immune system
abnormalities, allergies, and exposure of
children to drugs, infection, certain foods
or heavy metals have been proposed as
risk factor for autism
Iebba et al. (2011), Liu et al.
(2005), Sahley and Panksepp
(1987), Wills et al. (2007), Cohen
et al. (1982), Rossi-George et al.
(2011), Kinnell (1985), Cohen
et al. (1976)
The evidence for the discussed postnatal risk
factors needs further substantiation. While it
seems plausible that some of the factors can
affect brain development prenatally, their
postnatal mode of action needs further
investigation
Summary statements about each of the environmental factors. The quality of evidence produced by the published studies is weighted based on the replicability and
strength of association.
autism (Pardo et al., 2005). This hypothesis is underlined by many
reports of abnormalities in peripheral immune cells, as well as
associations between variants of genes for cytokines, their recep-
tors, and human leukocyte antigens (HLA) in autism (Patterson,
2009). It was shown that immune changes early in development
persist throughout development and aging and are still detectable
in the adult brain (Patterson, 2009). Despite these long lasting
changes, specific gestational windows may be associated with a
higher susceptibility to infection-mediated deregulations in brain
development (Meyer et al., 2007).
The risk for autism associated with prenatal infections is most
likely dependent on the individual immune status of the mother
and fetus. This is substantiated by the finding of a possible associ-
ation of autism with autoimmune disease and allergy, particularly
in the mother (Fox et al., 2012). Consequentially, maternal infec-
tion could alter the immune status of the fetal brain and the fetal
immune system in general, since the placenta serves as the source
of hematopoietic stem cells for the fetus (Gekas et al., 2005). A
pathology of the placenta has been linked to the development of
autism (Anderson et al., 2007).
ZINC DEFICIENCY
Metal ion homeostasis is essential for proper brain function and its
disruption is implicated in severe neurological symptoms and cog-
nitive diseases. Zinc (Zn2+) -deficiency has many different effects
on the brain. Zn2+ is the second most abundant trace element in
the body and thus not surprisingly, plays a role in many different
processes, such as cell division and differentiation. For instance,
hundreds of enzymes require Zn2+ for their functions (Takeda,
2001). Many studies have shown that Zn2+-deficiency affects sev-
eral brain functions and interferes with neuronal maturation via
impairment of Zn2+ dependent systems during early develop-
ment, resulting in severe brain dysfunctions such as irrecoverable
impairment of learning and memory. Approximately 90% of the
total brain Zn2+ is bound to proteins with free Zn2+mostly located
in presynaptic vesicles (Frederickson, 1989). However, transgenic
animals without presynaptic Zn2+ were not shown to develop
symptoms of autism. Recent studies have shown that Zn2+ ions
are able to modulate the PSD scaffold of synapses via the autism-
associated proteins Shank2 and Shank3 (Jan et al., 2002; Baron
et al., 2006).
Within the body,copper (Cu2+) and Zn2+ have competing roles
in a way that Cu2+ overload leads to Zn2+-deficiency (Hall et al.,
1979; Huster, 2010). Former studies describe a significant eleva-
tion of Cu2+ in the hair and nail samples of subjects with autism
(Lakshmi Priya and Geetha, 2011). Moreover, further studies indi-
cate that the Cu2+/Zn2+ ratio is increased in the serum of subjects
with autism (Faber et al., 2009) and was suggested as biomarker for
children with autism. However, Zn2+ deficiency might not only
be a biomarker for autism, but indeed a risk factor. Many autistic
children have Zn2+-deficiency (Walsh et al., 2001, 2002; Jen and
Yan, 2010; Yasuda et al., 2011). In a recent study, hair Zn2+ concen-
trations from 1,967 children with autism were investigated and an
incidence rate of Zn2+-deficiency in the infant-group aged 0–3-
year-old was estimated 43.5% in male and 52.5% in female. These
findings suggest that infantile Zn2+-deficiency may contribute to
the pathogenesis of autism (Yasuda et al., 2011).
Zn2+-deficiency causes neuropsychological symptoms, learn-
ing, and memory impairments (Golub et al., 1995), behavioral
problems and an enhancement of glutamate excitotoxicity. There-
fore, Zn2+-deficiency is also associated with the occurrence of
seizures (Grabrucker et al., 2011a) and many patients with autism
suffer from epilepsy.
Some candidate genes that have been identified so far to be
associated with the development of autism, such as COMMD1
(COMM domain-containing protein 1), MTF1 (metal regulatory
transcription factor 1), metallothioneins (MTs), ZnT5 (zinc trans-
porter 5), ERK1 (extracellular signal-regulated kinase 1), TrkB
(tyrosine-related kinase B), SHANK2, and SHANK3 (SH3 and
multiple ankyrin repeat domains 2/3, also known as proline-rich
synapse-associated protein (ProSAP1 and ProSAP2; Serajee et al.,
2004; Huang et al., 2008; Grabrucker et al., 2011b; Levy et al.,
2011; O’Roak et al., 2011; Nuttall and Oteiza, 2012; Sanders et al.,
2012), are influenced by Zn2+ or themselves involved in Zn2+-
signaling and metal ion homeostasis. Thus, Zn2+ might provide a
mechanism of gene/environment interaction and maternal Zn2+-
deficiency might act as risk factor for autism. Zn2+-deficiency in
pregnant rhesus monkeys has effects on the behavior of infants
(Sandstead et al., 1978). Intriguingly Zn2+-deficiency is known
to compromise the immune system, providing a possible link to
prenatal infections.
ABNORMAL MELATONIN SYNTHESIS
It was hypothesized that abnormalities in melatonin secretion may
play a role in the development of autism. Melatonin is an endoge-
nous neurohormone produced in the dark predominantly in the
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pineal gland and levels of melatonin or melatonin derivatives were
found to be often below average in individuals with ASD (Rossig-
nol and Frye, 2011). Along with the decreased levels of melatonin,
children with ASD have a higher prevalence of sleep abnormalities
such as longer “sleep onset latency,” frequent night-time awaken-
ings and reduced sleep duration (Rossignol and Frye, 2011). Sleep
problems in ASD might occur as a result of complex interactions
between genetic and social/environmental factors (Cortesi et al.,
2010). Circadian abnormalities in autism might be the result of
genetic abnormalities related to melatonin synthesis. Deletions of
the ASMT (acetylserotonin O-methyltransferase) gene, encoding
the last enzyme of melatonin synthesis, have been found in several
individuals with ASD (Melke et al., 2008). Additionally, environ-
mental factors can influence melatonin synthesis. For instance,
maternal stress was shown to result in reduced melatonin levels
(Feng et al., 2012) as well as light pollution (Reiter et al., 2006;
Falchi et al., 2011). Interestingly, Zn2+-deficiency has an effect on
various hormones such as melatonin. A reduction in Zn2+ levels
in pinealectomized rats suggests a reciprocal affect between Zn2+
and melatonin and a significant decrease in melatonin levels was
observed in Zn2+-deficient animals (Bediz et al., 2003).
Although melatonin is best known for its role as a key regu-
lator of the circadian rhythm, it is also a potent antioxidant, has
anti-inflammatory properties, is involved in the immune response,
and helps regulate synaptic plasticity (Rossignol and Frye, 2011).
Given that a low melatonin level can also be found in healthy indi-
viduals, it cannot be considered as a direct cause of ASD, but as a
susceptibility factor. The effects of maternal melatonin deficiency
on the offspring have not been investigated thoroughly in terms
of an association with ASDs.
MATERNAL DIABETES
Meta-analysis revealed diabetes in the mother during preg-
nancy as a risk factor for autism (Gardener et al., 2009) with a
twofold increased risk. Still, the pathological mechanisms remain
unknown. In line with these data, a study (Krakowiak et al., 2012)
found that metabolic conditions such as obesity, hypertension, or
diabetes could occur more frequently in mothers of ASD cases.
However, obesity alone was significantly associated with this risk
in this study, while only a trend was observed for hypertension and
diabetes.
PRENATAL AND PERINATAL STRESS
Several lines of evidence show significant effects of prenatal stress
activating the hypothalamic-pituitary-adrenal (HPA) axis on post-
natal behavior in human and animal studies. If autism can result
from prenatal stress is currently investigated and the duration,
severity, and type of stress are under debate. So far, autism has
been reported to be associated with prenatal stress both with ret-
rospective studies (Ward, 1990; Beversdorf et al., 2005) and by
comparison to historical events such as storm catastrophes. More-
over, animal studies have reported that prenatal stress produces
behaviors resembling symptoms of autism (Kinney et al., 2008).
Along with behavioral symptoms significant changes have been
found in the regulation of the HPA axis of these animals, regard-
less of the specific prenatal stressor used. Additionally, prenatal
exposure to either stress hormones or psychological stress of the
mother in rhesus monkeys resulted in abnormalities in postna-
tal immune function in infancy that were persistent throughout
late childhood (Coe et al., 1999). These immune functions such as
proliferation of lymphocytes, natural killer cell activity, and pro-
duction of cytokines, might decrease the ability to resist viral and
bacterial infections and thus the pathological mechanisms of pre-
natal stress might be related to the increased risk of autism seen
with prenatal infections. Stress can also be produced by compli-
cations of labor and delivery. Both are associated with greater risk
of hypoxia and cerebral hemorrhage in the newborn and a study
shows that those who survived cerebellar hemorrhagic injury had
a significantly increased risk to develop autism (Limperopoulos
et al., 2007).
TOXINS
Independent from maternal health, environmental agents are
threatening the development of a fetus, causing birth defects.
These so called teratogens have been suggested as potential risk
factor for autism. For example, the incidence of autism is signifi-
cantly higher in children prenatally exposed to the anticonvulsant
agent valproic acid (Moore et al., 2000) or the immunomodula-
tory agent thalidomide (Stromland et al., 1994) early in the first
trimester of gestation. Valproic acid for instance, an anticonvulsant
used in the treatment of epilepsy and also bipolar disorder due
to its mood-modifying ability, is a histone deacetylase inhibitor
and might change the methylation pattern of autism – associ-
ated genes, thereby affecting their expression rate. Intriguingly,
administration of valproic acid in utero leads to developmental
delays and lifelong deficits in motor performance, social behav-
ior, and anxiety – like behavior in the offspring (Kolozsi et al.,
2009). Along with this, Neuroligin 3 (NLGN3) mRNA expression
was significantly decreased in hippocampal CA1 region, dentate
gyrus, and somatosensory cortex of these animals (Kolozsi et al.,
2009). Nlgn3, a member of neuroligin family, is expressed in the
postsynaptic compartment of neurons and mediates transsynap-
tic signaling by interacting with neurexin (NRXN; Südhof, 2008).
Mutations in NLGN3 and NRXN have been reported as genetic
cause for ASD (Jamain et al., 2003).
Thalidomide, which was infamous for causing birth defects
when used as an antiemetic in pregnancy in 1950/1960 still is
of pharmacological interest given its immunomodulatory effects
(Kumar and Chhibber, 2011). The observed immunomodulation
by thalidomide might be related to the increased risk observed
through prenatal infection. Thalidomide, for instance, modu-
lates cytokine levels and macrophage pro-inflammatory function
(Kumar et al., 2010). It was also found to have anti-angiogenic and
immunomodulatory properties including T cell co-stimulation,
and activation of NK (natural killer) cells (Quach et al., 2010).
Prenatal exposure to organophosphate pesticides such as diazi-
non and chlorpyrifos, agents that have been shown to be neu-
rotoxic (Karr et al., 2007), may contribute to autism. A genetic
predisposition seems to enhance vulnerability for these substances
(Dufault et al., 2012). Additionally, a study found that women who
are in the first 8 weeks of pregnancy in closer contact with the
organochlorine pesticides dicofol and endosulfan due to their res-
idential proximity to sprayed fields, are several times more likely to
give birth to children with autism (Roberts et al., 2007). However,
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a limited number of cases and studies makes these findings hard
to interpret and the concordance rate is not 100%, which suggests
that a genetic predisposition might be necessary for a toxin to act
as trigger (Szpir, 2006).
A more solid association for a factor for the development of
autism can be found in the use of psychiatric drugs in the mother
during pregnancy (Gardener et al., 2009). The association of psy-
choactive medications could be achieved through various ways.
Since most of these drugs are able to cross the placenta, the effect
might indeed be caused by direct exposure to the psychoactive sub-
stance. Nevertheless, the actually treated condition of the mother
might itself have an influence on fetal development or reflect cer-
tain genetic traits that are possibly shared between autism and the
mother’s condition. Moreover, the need of psychoactive medica-
tion in the mother may hint towards a prenatal stress situation, a
condition that has been linked to autism before.
PARENTAL AGE
The risk to develop autism is associated with advanced age in
either parent (Gardener et al., 2009; Shelton et al., 2010; Parner
et al., 2012). A meta-analysis of epidemiological studies including
25,687 ASD cases and 8,655,576 control subjects investigating the
association between maternal age and autism supports advanced
maternal age as a risk factor for autism. The association still per-
sisted after considering effects of paternal age (Sandin et al., 2012).
Further studies indicate that the father’s age is of similar impor-
tance given that men transmit a much higher number of mutations
to their children than women (Kong et al., 2012) and that the age
of the father is the dominant factor in determining the number of
de novo mutations in the child (Kong et al., 2012). Thus, advanced
paternal age was similarly associated with increased risk of ASDs
in offspring (Croen et al., 2007; Grether et al., 2009; Reichenberg
et al., 2010; Shelton et al., 2010; Buizer-Voskamp et al., 2011; van
Balkom et al., 2012). However, advanced paternal and maternal
age may act as risk factors through different mechanisms. While
most small-scale de novo mutations accumulate in the paternal
germline over time related to parental age (Iossifov et al., 2012),
eggs are fully developed at the time of a mother’s birth. Thus,
advanced maternal age might contribute as risk factor for autism
through mechanisms such as increased pregnancy complications
(Gardener et al., 2009) and maternal autoimmunity (Enstrom
et al., 2009). The risk factor of maternal autoimmunity again
hints towards the involvement of an immune response during
pregnancy as a risk factor for autism. Pro-inflammatory cytokines
possibly arising from maternal autoimmunity might cause aber-
rant neuronal growth and function within the developing fetal
brain (Buehler, 2011).
POSTNATAL RISK FACTORS
Although it is assumed that children are born with autism, a wide
variety of postnatal factors contributing to autism have been pro-
posed (Table 1). However, the evidence for these risk factors, such
as gastrointestinal or immune system abnormalities, allergies, and
exposure of children to drugs, infection, certain foods, or heavy
metals needs further substantiation. Vaccination can no longer
be regarded as risk factor for autism (Doja and Roberts, 2006).
Evidence from several rigorous scientific studies examining an
association between vaccine use and autism have not identified
such a link (Miller and Reynolds, 2009) and the data of former
studies claiming an association were shown to be scientifically
fraudulent (Flaherty, 2011).
Gastrointestinal abnormalities, in terms of the “Leaky gut syn-
drome” as risk factor for autism are based on parents reporting
gastrointestinal disturbances in autistic children, and several stud-
ies have investigated possible associations between autism and the
gut (Liu et al., 2005; Iebba et al., 2011). Additionally, a connection
between autism and opiates was proposed (Sahley and Panksepp,
1987). Caused by a digestive disorder, gluten, and casein might be
converted to the opioid peptides gliadorphin and casomorphin,
thus influencing the development of autism. However, more evi-
dence is needed to verify that autistic children are more likely
to have gastrointestinal pathologies than control children. Nev-
ertheless, it is tempting to speculate that a possible link between
malnutrition, gastrointestinal abnormalities, and Zn2+-deficiency
reported as risk factors for autism may exist. Similarly, Zn2+-
deficiency might influence the immune system and it was hypoth-
esized that autoantibodies that compromise brain development
or important metabolic pathways may be a risk factor for autism.
Similar to maternal antibodies, via an autoimmune mechanism,
own antibodies may cause an aberrant immune activity (Wills
et al., 2007).
Heavy metal poisoning by mercury and lead have been associ-
ated with autism. Given that elevated lead levels in the blood of
autistic children have been found, lead poisoning has been sug-
gested as a possible risk factor (Cohen et al., 1982). Lead and stress
share biological substrates and produce common adverse effects
(Rossi-George et al., 2011). However, the evidence so far is indirect
for the association between autism and mercury or lead exposure
after birth. Moreover, atypical eating behaviors of autistic chil-
dren, such as seen in “pica” (the persistent eating of non-nutritive
substances for a period of at least 1 month; Kinnell, 1985) may
influence lead levels more than being a consequence of autism
(Cohen et al., 1976).
ENVIRONMENTAL FACTORS IN AUTISM – A MODEL
Taken together, there is overwhelming evidence that autism is a
genetic disorder. Twin studies indicate a genetic basis for autism
and genome wide association studies have revealed some inter-
esting candidate genes (Miles, 2011; Li et al., 2012). Nevertheless,
environmental factors can have an obvious influence on the devel-
opment of autism. It is tempting to speculate that most of the
identified risk factors so far, such as prenatal stress, prenatal infec-
tion, maternal Zn2+-deficiency, and maternal exposure to toxins as
well as potential novel factors that will be identified in the future
might indeed all be different sides of the same coin. Thus, the
search for similarities in all the identified genetic as well as environ-
mental factors might lead to a time window in brain development,
where certain brain regions and specific pathways are prone to dis-
ruption caused by various agents but all leading to the phenotype
of autism. Figure 1 shows an attempt to unite the several environ-
mental risk factors identified in autism so far and tries to bridge
the gap between these and genetic factors (Figure 1). From this
analysis, two central motifs, immune system abnormalities, and
Zn2+-deficiency, emerge.
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FIGURE 1 | Interconnection of various environmental risk factors for
autism. Many risk factors for autism can be related to each other. All factors
are shown weighted for their interconnectedness with other factors.
Zn2+-deficiency and immune system aberrations receive most connections
and thus can be placed in the center of the network. Zn2+-deficiency, toxins,
and the parental age may act on genetic factors providing a crosstalk
between genes and environment. Zn2+-deficiency and melatonin deficiency in
turn can also be caused by genetic alterations.
A close connection exists between a functional immune system
and the development of the central nervous system and a suc-
cessful neurodevelopment requires a normal balance of immune
responses (Ashwood et al., 2006). Immune system abnormalities
might result from toxins that compromise important players of
the system, stress, parental age, Zn2+-deficiency, and infections.
Prenatal stress in turn was associated with an abnormally devel-
oping HPA system, an affected placenta as well as hippocampal
volume reduction. Smaller hippocampal volumes in turn are asso-
ciated with an increased secretion of cortisol (Frodl and O’Keane,
2012). Intriguingly, patients with ASD were characterized by a
significant reduction of gray matter volume in the amygdala-
hippocampus complex (Via et al., 2011). Cortisol as the primary
end product of the HPA axis is an important component of the
stress system in humans and essential for fetal growth and the
induction of specific enzymes (Charil et al., 2010). Therefore,
women have naturally elevated levels of cortisol during preg-
nancy. However, it is possible that maternal cortisol concentra-
tions can reach abnormally high levels under particular stressful
conditions. Cortisol that reaches the fetus may potentially alter
fetal development and growth. Animal studies have shown that
fetal exposure to high levels of cortisol alters neuronal develop-
ment and results in a smaller hippocampal size (Charil et al.,
2010).
The placenta is similarly affected by prenatal stress and releases
Corticotropin releasing factor (CRF) from the placenta during
sub-acute and chronic prenatal stress that may cross the blood-
brain barrier of the fetus. Consequently, the function and integrity
of the hippocampus is affected, for instance by an increase in
release of acetylcholine, inhibiting the influence of cholinergic
receptors on the activity of the HPA axis (Charil et al., 2010).
Parental age is correlated with an increased risk of maternal
autoimmunity as the majority of autoimmune disorders are man-
ifest between 30 years of age and upward (Ashwood et al., 2006).
Autoimmune disorders arise when the immune system is inap-
propriately directed to recognize and response to self-components
and maternal autoantibodies may affect fetal brain development
during critical periods of neurodevelopment (Chonchaiya et al.,
2010). Components of the immune system such as cytokines
and autoantibodies, may act to increase fetal cytokine signaling
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and expression, disrupt trophic factor, and apoptotic signaling,
as well as modulate cytoarchitecture in the CNS (Murphy et al.,
2010). Prevalence rates suggest that autoimmune diseases, such as
rheumatoid arthritis, autoimmune thyroid diseases, myasthenia
gravis, multiple sclerosis, systemic lupus erythematosus (SLE), and
primary biliary cirrhosis are not uncommon, affecting approxi-
mately 5% of women and 3% of men in the USA (Murphy et al.,
2010).
Prenatal infections could persistently alter the immune status
of the fetus. An inflammatory-like state has been detected in post-
mortem brains of autism patients, indicated by elevated cytokines
and activated microglia and astrocytes. Moreover, cytokine ele-
vation was also found in the cerebrospinal fluid (CSF) of liv-
ing autistic children (Pardo et al., 2005). Cytokine IL-6 thereby
attracted special attention. IL-6 leads to a reduction in insulin-like
growth factor (IGFs)-binding protein 3 and IGF1 (IGFs 1; Pat-
terson, 2009). Intriguingly, IL-6 also regulates Zn2+ binding MTs
(Manso et al., 2011). Animal studies suggest that these inflam-
matory changes might ultimately alter NMDA receptor mediated
excitatory synaptic transmission and plasticity in the hippocam-
pus (Escobar et al., 2011). The inflammatory-like state was also
detected in the peripheral immune system. Immune cell may infil-
trate into the colon, ileum, and duodenum and an increased T
cell activation can be present in the intestinal mucosa. Thus, these
inflammatory changes may also lead to gastrointestinal abnor-
malities. However, in terms of prenatal infections it is unclear, if
the infection itself causes an imbalance of the immune system or
if a compromised immune system in the first place leads to an
increased susceptibility for infections.
The second central environmental factor is Zn2+-deficiency.
Zinc is an essential trace element and plays various roles in bio-
logical processes. For instance, Zn2+ is a structural component of
proteins and involved in enzymatic processes and a transcriptional
regulator (Tuerk and Fazel, 2009). Zn2+-deficiency itself influ-
ences the immune system and low Zn2+ status has been associated
with an increased susceptibility for infections (Wong and Ho,
2012). Zn2+-deficiency significantly impairs both adaptive and
innate immune responses, and promotes systemic inflammation.
Zn2+ is essential for normal development and function of cell-
mediating innate immunity, neutrophils, and natural killer cells.
For instance, macrophages, phagocytosis, intracellular killing, and
the growth and function of T and B cells are all affected by Zn2+-
deficiency. Zn2+-deficiency also affects the production, secretion,
and functions of cytokines (see thalidomide), the basic mes-
sengers of the immune system (Prasad, 2009). Cytokines have
widespread effects on neuronal pathways and are able to show
behavioral effects such as alteration of mood and sleep (Ash-
wood et al., 2006). Imbalances in the immune system were seen in
humans with induced mild Zn2+-deficiency within 12 weeks of a
Zn2+-restricted diet (Prasad, 2009).
Zn2+ homeostasis is also highly regulated via the gastrointesti-
nal tract (Tuerk and Fazel, 2009) and gastrointestinal abnormal-
ities have been mentioned as risk factor for autism. Moreover,
viral infections might affect the gastrointestinal system providing
another link between immune system abnormalities and Zn2+-
deficiency. However, Zn2+-deficiency can be caused by many
factors that have been associated with autism in the past, such as
maternal diabetes,malnutrition,copper overload,and atypical eat-
ing behavior. Maternal diabetes and obesity have been associated
with this risk to develop autism and may influence the developing
child similar to malnutrition. Vegetarian diet usually provides a
low intake of Zn2+ (Craig, 2010) and also fiber rich diet, suggested
for diabetes (Wolfram and Ismail-Beigi, 2011), increases the risk of
Zn2+-deficiency (Foster et al., 2012). Intriguingly the consump-
tion of fiber rich diet within the USA increased in the last decades
(Hiza and Bente, 2007).
Within the body Cu2+ and Zn2+ have competing roles in a
way, where Cu2+ overload leads to Zn2+-deficiency (Hall et al.,
1979; Huster, 2010). Cu2+ overload in an extreme form is seen
in patients suffering from Wilson’s disease, where homozygous
mutation of the ATP7B gene results in Cu2+ accumulation in tis-
sues manifesting in neurological or psychiatric symptoms among
others. Although the disease is rather rare, the heterozygous form
with only one faulty copy of the affected gene is not so rare. It
was speculated that in this case, the developing fetus of a pregnant
woman may experience major difficulties in the early development
of the brain due to a Cu2+ overload – induced Zn2+-deficiency,
which may later manifest as autism (Johnson, 2001). Atypical eat-
ing behaviors in autism, such as pica, in turn may influence again
the nutritional status but also cause heavy metal poisoning. In this
case, both scenarios would be postnatally affecting the develop-
ment of autism. Nevertheless, a heavy metal intoxication during
pregnancy might again disturb Zn2+ homeostasis.
Melatonin deficiency may be the result and cause of a Zn2+-
deficiency. Melatonin also has an impact on the immune system,
thus possibly influencing both major identified environmental
factors for the development of autism.
Severe Zn2+-deficiency is rare and mostly occurs in developing
countries. Marginal Zn2+-deficiency in contrast, is a potentially
widespread problem. Based on a study of 14,770 individuals aged
3–74 years, the prevalence of Zn2+-deficiency in the USA was esti-
mated with 1–3 and 10% of the US population consumes less than
half the recommended level for Zn2+ and thus is at risk for Zn2+-
deficiency (Tuerk and Fazel, 2009; Wong and Ho, 2012). Moreover,
women may not ingest adequate amounts of Zn2+ during preg-
nancy (Halas and Sandstead, 1975) and suffer from decreased
levels of Zn2+ during the latter part of pregnancy (Halsted and
Smith, 1970; Sandstead, 1973). However, since Zn2+-deficiencies
can be found in many brain disorders such as schizophrenia and
depression (Grabrucker et al., 2011a), more research is needed to
investigate the cause of these Zn2+-deficiencies.
Intriguingly, environmental factors such as Zn2+-deficiency
might have a crosstalk with genetic factors. Some autism can-
didate genes that have been identified so far, such as COMMD1,
MTF1, MTs, ZnT5, ERK1, TrkB, Shank2, and Shank3 (Serajee et al.,
2004; Huang et al., 2008; Grabrucker et al., 2011b; Levy et al.,
2011; O’Roak et al., 2011; Nuttall and Oteiza, 2012; Sanders et al.,
2012), are influenced by Zn2+ or themselves involved in Zn2+
signaling and metal ion homeostasis. The idea that many genes
implicated in autism might converge on a single pathway present at
excitatory glutamatergic synapses has recently been raised by mul-
tiple studies and a Nrxn-Nlgn-Shank pathway has been proposed
(Bourgeron, 2009). Thus, Shank proteins, via their dependency
on Zn2+ ions (Grabrucker et al., 2011c), might influence further
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autism-associated proteins. For instance, mGluR5, an important
target in fragile-X-syndrome is an interaction partner of Shank
proteins (Lim et al., 1999). However, it is possible that other
identified autism-associated genes have different crossing points
with the environmental risk factors for autism discussed here and
future research will picture the model of environmental factors
influencing genetic predispositions for autism in more detail.
ENVIRONMENTAL FACTORS IN AUTISM –MODES OF ACTION
Given this interconnectedness of many environmental and genetic
factors associated with the development of autism, one can spec-
ulate how these risk factors might converge an a single hypo-
thetical pathway by looking at possible similarities in the mode
of action. Autism is caused by abnormalities in the structure
or functions of the brain, but the underlying biological patho-
mechanisms are currently not well understood. However, various
recent studies have identified copy number variations (CNVs)
as well as single nucleotide polymorphisms (SNPs) of neuronal
genes in the genomes of ASD patients. Many of these genes
encode proteins that are crucial components of excitatory glu-
tamatergic synapses, including scaffold proteins such as Shank2,
Shank3, SAPAP2 from the GKAP/SAPAP family of Shank inter-
acting proteins, neural adhesion molecules, such as Neuroligins,
Neurexins as well as Cadherins, Contactin, Contactin-associated
protein,and other cell-adhesion molecules (CAMs), calcium chan-
nels, and neurotransmitter receptors (Betancur et al., 2009; Pinto
et al., 2010; Toro et al., 2010). Moreover, protein kinases and
proteins that regulate protein syntheses have been identified as
candidate genes associated with ASD. Mouse models for these
genes underline their role in autism and hint towards a dereg-
ulation of excitatory synapses since all these proteins play a
role at the synapse of glutamatergic neurons. Thus, these data
imply a link between a synaptic pathology and the characteris-
tics of ASD and shift the synaptic compartment in the focus of
interest.
To study a crossing point of environmental factors with
genetic predispositions and the development of autism, excitatory
synapses may provide a useful starting point. Given that a synap-
topathy is the underlying mechanism for autism and focusing on
the two central environmental factors “immune system abnormal-
ities” and “zinc deficiency,” similarities can be found influencing
synaptic function and plasticity (Figure 2).
Abnormalities in the immune system are known to result in
altered cytokine and major histocompatibility complex (MHC)
expression and release of nitric oxide (NO) and cyclo-oxygenase
products on a molecular level. Thus, inflammatory responses
can have several effects on the brain. Circulating immune cells
may infiltrate the CNS, resident cells are activated and pro-
inflammatory mediators such as cytokines are produced and
released. These immune diffusible mediators may influence synap-
tic processes such as long-term potentiation (LTP; Di Filippo
et al., 2008), a molecular mechanism thought to underlie synaptic
plasticity in learning and memory formation. LTP manifests as
a persistent increase of the evoked response following repeated
synaptic activation. The generation of LTP requires activation
of postsynaptic NMDA receptors, subsequent postsynaptic Ca2+
entry together with the induction of several signaling systems and
finally gene transcription and new protein synthesis (Malenka
and Nicoll, 1999). Cytokines and other molecules overexpressed
during the neuroinflammatory process act as neuromodulators
with pro-inflammatory cytokines showing a detrimental effect on
neuronal function, viability, and plasticity (Allan and Rothwell,
2001) even when expressed at low levels. In particular, the release
of neurotransmitter is influenced as well as signal transduction
mechanisms within the postsynaptic density (PSD) and, finally,
the ability to induce LTP.
For instance, IL-1 crucially influences several key molecular
components of LTP – induction, such as NMDA and AMPA recep-
tor signaling (Coogan and O’Connor, 1997; Lai et al., 2006) and
glutamate release (Murray et al., 1997). Similarly, IL-18, a member
of the IL-1 family, is able to impair the induction of LTP, probably
by negatively modulating NMDA receptor mediated transmission
in the hippocampus (Curran and O’Connor, 2001). However, the
effects of IL-1 on NMDA and AMPA receptors have not been
completely elucidated to date and might be brain region specific.
IL-6 is thought to modulate the ERK pathway, a signaling pathway
involved in the generation of LTP. Additionally, an increase in IL-6
leads to a reduction in IGFs-binding protein 3 and IGF1 (Patter-
son, 2009). Intriguingly, IL-6 also influences one of the major Zn2+
stores in postsynapses, the Zn2+ binding MT proteins (Manso
et al., 2011).
IL-18, IL-1β, and TNF-α (Tumor necrosis factor alpha) act on
AMPA and NMDA as well as metabotropic receptor signaling,
thereby modulating the activity of the stress activated p38 MAPK.
TNF-α, a pro-inflammatory cytokine binds to receptors, which
are expressed on neurons and glial cells throughout the CNS.
Interestingly, the inhibition of mGluR1 and mGluR5 can block
the TNF-α – dependent inhibition of early and late LTP. Thus, a
combined activation of TNF receptors and mGluRs may impair
the formation of LTP, although the exact mechanism of TNF and
mGlu receptor activation is still not well understood (Pickering
et al., 2005).
Besides their role as modulators of brain growth, IGFs also
influence brain plasticity. Specifically, IGFs regulate synapse for-
mation, neurotransmitter release, and neuronal excitability via
posttranslational modification of NMDA and AMPA receptors
(Torres-Aleman, 1999). IGF1 acts primarily on the IGF1 recep-
tor, which is neuronally expressed and coupled to the PI3K-AKT
signal transduction pathway that positively influences cellular
growth and thus affects the maturation of outgrowing neurites
and synapse like structures. In the case of IGF1, this feature has
already been used therapeutically in preclinical settings, where the
application of recombinant IGF1 was demonstrated to improve
synaptic maturation in a mouse model for Rett syndrome, a type
of ASD (Tropea et al., 2009). Moreover, a crosstalk between IGFR
activation and the ERK pathway can be found.
Thus, immune system abnormalities might ultimately alter
NMDA receptor mediated excitatory synaptic transmission and
plasticity (Escobar et al., 2011). Similar results have already been
shown in animal studies where changes in NMDAR responses and
NMDAR dependent LTP as well as an imbalance in NMDAR levels
and subunit composition were reported in recent mouse models
for autism (Bangash et al., 2011; Wang et al., 2011; Schmeisser
et al., 2012; Won et al., 2012).
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FIGURE 2 | Modes of action of environmental risk factors for autism at
excitatory synapses in the CNS. Scaffold proteins within the PSD such as
proteins of the Shank family build a dense meshwork of interacting protein
complexes including Homer, mGluR, AMPAR, and GKAP further connecting to
PSD95 and NMDAR. These synaptic components are regulated via signaling
cascades such as the p38 MAPK and ERK pathway and altogether ultimately
determine the immediate and long-term response to a synaptic stimulus.
Environmental factors that have been discussed in autism may influence this
signaling outcome on various levels. Zn2+-deficiency for instance might be
able to alter the PSD scaffold via Shank2 and Shank3 and additionally
influences NMDAR, TrkB receptor, and GPR39 receptor signaling. Moreover,
Zn2+ that might be released from presynaptic vesicles or postsynaptic
metallothioneins can affect IGF1 signaling and gene expression via MTF1.
Immune system abnormalities, including the expression of cytokines such as
TNF-α, Il-1β, IL-18, and IL-6 will affect mGluR, p38 MPAK, and ERK signaling,
pathways that are also activated by the receptors mentioned above.
Prenatal stress might additionally contribute to the above –
mentioned effects via CRF secretion. Stress in known to influence
synaptic transmission in brain regions, such as hippocampus, ulti-
mately affecting learning, and memory. Whereas physiological
levels of CRF augment memory processes, exposure of high levels
of the peptide results in retraction of dendritic spines of excitatory
synapses in the hippocampus and amygdala and thus to synapse
loss. Although only a minority of dendritic spines is lost due to
long lasting CRF exposure, a profound memory impairment and
loss of LTP can be observed (Chen et al., 2012). However, the mol-
ecular mechanisms of this synapse loss are not fully understood.
Intriguingly, CRF activates, through CRF1, the ERK pathway in
the area CA3 of the hippocampus.
The idea of Zn2+ being a regulatory core component within
PSDs results in novel insights and understanding concerning
synapse formation and might hint towards a mechanism of Zn2+-
deficiency in autistic patients. Indeed several autism-associated
genes that can be found at excitatory postsynapses, such as Shank2
and Shank3, MTs and ERK are Zn2+ binding, and Zn2+ regu-
lated proteins. Shank proteins further connect to mGluR, GKAP,
Neuroligins, and Neurexins. To date, the source of postsynaptic
Zn2+ involved in synaptic plasticity is still unclear and might
include presynaptic vesicular Zn2+ and/or postsynaptic activity
dependent release from Zn2+ stores such as MTs. Focusing on
excitatory synapses, it has been shown that Zn2+ influences the
activity of glutamate receptors. NMDA receptors have a very high
sensitivity to extracellular Zn2+ and the activity of GluN2A sub-
unit containing NMDA receptors is inhibited allosterically at low
nanomolar concentrations, while at micromolar Zn2+ concentra-
tions that may occur during synaptic activity, Zn2+ binds to the
GluN2B subunit, inhibiting GluN2B-containing receptors (Sensi
et al., 2011).
Zn2+ also activates a specific metabotropic Zn2+-sensing
receptor GPR39, which triggers IP3 production, followed by
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intracellular Ca2+ and subsequent activation of ERK and
CAMKII-dependent pathways (Besser et al., 2009). Moreover,
Zn2+ directly promotes the transactivation of the BDNF (brain-
derived neurotrophic factor)-related TrkB pathway (Huang et al.,
2008) and maternal Zn2+-deficiency decreases BDNF expression
in the offspring (Chowanadisai et al., 2005). In a recent study,
NTFs (neurotrophic factors) were measured in 414 ASD cases
and 820 controls. ASD cases were more likely to have significantly
decreased BDNF levels and significantly lower TGF-β (transform-
ing growth factor beta) levels were detected in females with ASD.
These data hint towards decreased NTFs levels during neonatal
period as risk factor for ASD contributing to the pathophysiology
of ASD through impairments of neuroplasticity (Abdallah et al.,
2012).
Given that Zn2+ increases IGF1 receptor sensitivity, Zn2+ also
affects IGF1 signaling in a way that Zn2+-deficiency may decrease
IGF1 receptor binding (McCusker and Novakofski, 2004). In gen-
eral, neurons control cytosolic Zn2+ levels tightly using several
ZnT transporters, ZIP transporters, and Zn2+ buffering MTs and
Zn2+-deficiency might influence all of the above – mentioned
pathways and proteins. Thus, the many faces of Zn2+ taking part
in such a high number of biological and synaptic processes makes
it hard to pinpoint the mechanism involved in the development
of autism and the presented model might have to be expanded in
the future.
Taken together, two major targets of environmental factors con-
tributing to the development of autism can be found on a synaptic
level. The first is the structural composition of synapses that
might be altered through deletions or mutations in key scaffold or
CAMs such as Neurexin, Neuroligins, GKAP, and proteins of the
ProSAP/Shank family. This might ultimately result in changes in
receptor number, or composition influencing NMDAR, AMPAR,
and mGluR and affect signaling components within the PSD. For
instance, Zn2+ depletion was shown to cause a decrease in Shank3
and NMDAR levels of forming synapses in vitro (Grabrucker et al.,
2011c). Loss of Shank3 in turn affects transsynaptic signaling via
Neuroligin-Neurexin complexes (Arons et al., 2012) and mGluR5
signaling (Verpelli et al., 2011) and Shank3 knock-out mice dis-
play a reduction of AMPAR and NMDAR (Bozdagi et al., 2010;
Bangash et al., 2011). Intriguingly, prenatal exposure to valproic
acid leads to reduced expression of the synaptic adhesion molecule
Neuroligin 3 in mice (Kolozsi et al., 2009).
The second major target is the p38 MAPK (mitogen-activated
protein kinase) and ERK pathway. ERK regulates two cellular
processes closely associated with plasticity: synaptic delivery of
AMPAR (Zhu et al., 2002), and activity dependent dendritic spine
modifications (Goldin and Segal, 2003). ERK kinases are them-
selves heavily influenced by the local Zn2+ concentration (Nuttall
and Oteiza, 2012). Additionally, ERK2 knock-out mice exhibit
marked anomalies in multiple aspects of social behaviors related
to facets of ASDs and impaired long-term memory (Satoh et al.,
2011). Moreover, Zn2+ signaling via GPR39 further alters the
receptor composition of excitatory synapses. Thus, both, alter-
ations in synapse morphology induced by structural changes and
disturbed signaling by kinases might converge leading to disrupted
LTP formation and plasticity at synapses. Therefore, a specific
decrement in excitatory signaling caused by various factors, such
as genetic mutations or environmental factors like immune sys-
tem abnormalities or Zn2+-deficiency, will ultimately lead to an
imbalance of inhibition and excitation. An imbalance of excitation
and inhibition was already proposed as underlying cause of autism
(Rubenstein and Merzenich, 2003).
Of course, the proposed model is an oversimplification and
should be considered a starting point rather than a finalized con-
cept. Many studies have not been considered here and might add,
revise, or refine the interactions described above. For instance,
the incorporation of novel risk factors or brain region specific
effects might deepen the understanding of environmental factors
in autism and of autism itself.
CONCLUSION
Experimental research often is designed in a way that one com-
ponent of a system is manipulated and the various outcomes
documented. For example, a transgenic mouse model with the
knock-out of a specific gene might display a pleiotropy of symp-
toms depending on the specific role of the encoded protein.
However, the cause for these various symptoms is known, since
only a single gene has been manipulated.
In the case of autism, current research faces the inverse situ-
ation. Many symptoms are observed and many significant asso-
ciations of environmental as well as genetic factors were found.
What is missing so far is a hypothesis, unifying all those different
factors chasing autism back to a single cause, for instance the dis-
turbance of a specific synaptic pathway that is influenced by genetic
and environmental factors. The fact that many autism-associated
genes are interconnected and that also many environmental fac-
tors seem to be related and impact genetic factors makes this goal
look achievable in the future. Like a necklace of pearls, where a
cut between two single parts at a random position in the chain
will lead to the drop of every pearl, the deregulation of this envi-
ronmentally influenced genetic pathway at any level may results
in autism. However, it is likely that the cut in the signaling chain
might influence the occurrence and severity of specific features of
autism.
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